Apr 26, 2016 at 20:00 | Source: PTI
Biotechnology firm Biocon today said its product portfolio will not be affected by an order of the Delhi High Court that prevented the company from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin.
Apr 05, 2016 at 10:41 | Source: Moneycontrol.com
It believes that Biocon's (and its partner Mylan) four potential product filings each in the US and EU would add credibility to its pipeline and bring market recognition. Emerging market monetisation is under way, but the US and EU opportunities will take at least two years, according to report.
Sep 15, 2015 at 16:45 | Source: PTI
GBR 1302, a bi-specific monoclonal antibody, is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.
Feb 07, 2014 at 22:27 | Source: CNBC-TV18
The Delhi High Court (HC) has thrown a wrench into plans of Biocon and Mylan to market a breast cancer drug that goes by the scientific name Trastuzumab.
Feb 04, 2014 at 09:59 | Source: PTI
The company's subsidiary Mylan Pharmaceuticals Pvt Ltd has launched the world's first trastuzumab biosimilar, which will be marketed by Mylan under the brand name Hertraz Herceptin, a company statement said.
Jan 18, 2014 at 16:21 | Source: Reuters
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.
Nov 26, 2013 at 14:42 | Source: Moneycontrol.com
Biocon has received marketing authorization from the Drugs Controller General of India for its Biosimilar Trastuzumab being developed jointly with Mylan, for treatment of Her 2+ metastatic breast cancer.